CoChat

Selection of artemisinin partial resistance Kelch13 mutations in Uganda in 2016-22 was at a rate comparable to that seen previously in South-East Asia

Meier-Scherling, Cecile P. G., Watson, Oliver J, Asua, Victor, Ghinai, Isaac, Katairo, Thomas, Garg, Shreeya, Conrad, Melissa, Rosenthal, Philip J., Okell, Lucy C, Bailey, Jeffrey A. · 2024
PreprintCited by 9

The DOI matches its Crossref record.

Abstract

Background: Artemisinin partial resistance, mediated by mutations in the Plasmodium falciparum Kelch13 protein (K13), rapidly spread in South-East Asia (SEA), undermining antimalarial efficacies of artemisinin-based combination therapies (ACT). Validated K13 mutations have recently arisen in Africa, but rates of increase are not well characterized. Methods: We investigated K13 mutation prevalence at 16 sites in Uganda (2016-2022, 6586 samples), and five sites in SEA (2003-2018, 5465 samples) by calculating selection coefficients using Bayesian mixed-effect linear models. We then tested whether SEA K13 mutation prevalence could have been forecast accurately using up to the first five years of available data and forecast future K13 mutation prevalence in Uganda. Findings: The selection coefficient for the prevalence of relevant K13 mutations (441L, 469F/Y, 561H, 675V) was estimated at s=0·383 (95% CrI: 0·247 - 0·528) per year, a 38% relative prevalence increase. Selection coefficients across Uganda were s=0·968 (0·463 - 1·569) for 441L, s=0·153 (- 0·445 - 0·727) for 469F, s=0·222 (−0·011 - 0·398) for 469Y, and s=0·152 (−0·023 - 0·312) for 675V. In SEA, the selection coefficient was s=−0·005 (−0·852 - 0·814) for 539T, s=0·574 (−0·092 - 1·201) for 580Y, and s=0·308 (0·089 - 0·536) for all validated K13 mutations. Forecast prevalences for Uganda assuming constant selection neared fixation (>95% prevalence) within a decade (2028-2033) for combined K13 mutations. Interpretation: The selection of K13 mutations in Uganda was at a comparable rate to that observed in SEA, suggesting K13 mutations may continue to increase quickly in Uganda. Funding: NIH R01AI156267, R01AI075045, and R01AI089674.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1101/2024.02.03.24302209

Cites

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

No references could be resolved yet.

Research works printed but not linked: 25

  1. 10.1136/bmjgh-2018-000999 · DOI · Paper page
  2. Phillips MA , Burrows JN , Manyando C , van Huijsduijnen RH , Van Voorhis WC , Wells TNC . Malaria. Nat Rev Dis Primer 2017; 3: 17050. · DOI · Paper page
  3. 2022, Pre-existing partner-drug resistance to artemisinin combination therapies facilitates the emergence and spread of artemisinin resistance: a consensus modelling study, Lancet Microbe, 3, e701, 10.1016/S2666-5247(22)00155-0 · DOI
  4. 10.1056/NEJMoa0808859 · DOI · Paper page
  5. 10.1038/nature12876 · DOI · Paper page
  6. 10.7554/eLife.66277 · DOI · Paper page
  7. 10.1016/S1473-3099(21)00142-0 · DOI · Paper page
  8. 10.3201/eid2404.170141 · DOI · Paper page
  9. 10.1056/NEJMoa2101746 · DOI · Paper page
  10. 2019, Changing Molecular Markers of Antimalarial Drug Sensitivity across Uganda, Antimicrob Agents Chemother, 63, e01818
  11. 2020, Changing Prevalence of Potential Mediators of Aminoquinoline, Antifolate, and Artemisinin Resistance Across Uganda, J Infect Dis, 223, 985
  12. 2022, Decreased susceptibility of Plasmodium falciparum to both dihydroartemisinin and lumefantrine in northern Uganda, Nat Commun, 13, 6353, 10.1038/s41467-022-33873-x · DOI
  13. 10.1056/NEJMoa2210956 · DOI · Paper page
  14. 2023, Plasmodium falciparum resistant to artemisinin and diagnostics have emerged in Ethiopia, Nat Microbiol, 8, 1911, 10.1038/s41564-023-01461-4 · DOI · Paper page
  15. 10.4269/ajtmh.15-0477 · DOI · Paper page
  16. WWARN K13 Genotype-Phenotype Study Group, 2019, Association of mutations in the Plasmodium falciparum Kelch13 gene (Pf3D7_1343700) with parasite clearance rates after artemisinin-based treatments-a WWARN individual patient data meta-analysis. BMC Med, 17, 1
  17. 10.1056/NEJMoa2211803) · DOI · Paper page
  18. 10.1093/molbev/msw228 · DOI
  19. Zupko RJ , Nguyen TD , Ngabonziza JCS , et al. Potential policy interventions for slowing the spread of artemisinin-resistant pfkelch R561H mutations in Rwanda. 2022; : 2022.12.12.22283369. · DOI
  20. 2023, Pf7: an open dataset of Plasmodium falciparum genome variation in 20,000 worldwide samples. Wellcome Open Res, 8, 22
  21. 2013, Efficacy of Dihydroartemisinin-Piperaquine for Treatment of Uncomplicated Plasmodium falciparum and Plasmodium vivax in Cambodia, 2008 to 2010. Antimicrob Agents Chemother, 57, 818
  22. 10.1093/molbev/msg162 · DOI · Paper page
  23. van Schalkwyk DA , Pratt S , Nolder D , et al. Treatment failure in a UK malaria patient harbouring genetically variant Plasmodium falciparum from Uganda with reduced in vitro susceptibility to artemisinin and lumefantrine. Clin Infect Dis 2023; : ciad724. · DOI
  24. 2019, Impact of seasonal variations in Plasmodium falciparum malaria transmission on the surveillance of pfhrp2 gene deletions, eLife, 8, e40339, 10.7554/eLife.40339 · DOI
  25. 2023, Modeling policy interventions for slowing the spread of artemisinin-resistant pfkelch R561H mutations in Rwanda, Nat Med, 29, 2775, 10.1038/s41591-023-02551-w · DOI

Cited by

See all 9

Metadata

Authors
Meier-Scherling, C. P. G., Watson, O. J., Asua, V., Ghinai, I., Katairo, T., Garg, S., Conrad, M., Rosenthal, P. J., Okell, L. C., & Bailey, J. A.
Publisher
openRxiv
Published
2024-02-04
Cited by
9
References
0
Type
Preprint

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Selection of artemisinin partial resistance Kelch13 mutations in Uganda in 2016-22 was at a rate comparable to that seen previously in South-East Asia. https://app.cochat.ai/papers/10.1101/2024.02.03.24302209
The paper
Meier-Scherling, C. P. G., Watson, O. J., Asua, V., Ghinai, I., Katairo, T., Garg, S., Conrad, M., Rosenthal, P. J., Okell, L. C., & Bailey, J. A. (2024). Selection of artemisinin partial resistance Kelch13 mutations in Uganda in 2016-22 was at a rate comparable to that seen previously in South-East Asia. https://doi.org/10.1101/2024.02.03.24302209

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.